UAE | Health
Doctors welcome decision to make Avandia available
Physicians in the country heaved a sigh of relief following an announcement that popular diabetes drug Avandia will remain available, albeit with stronger warnings for increased heart risks, following a recommendation from the US drug authority.
- By Nina Muslim, Staff Reporter
- Published: 00:00 August 5, 2007
Dubai: Physicians in the country heaved a sigh of relief following an announcement that popular diabetes drug Avandia will remain available, albeit with stronger warnings for increased heart risks, following a recommendation from the US drug authority.
A panel of external experts recommended to the US Food and Drug Administration (FDA) on Monday that Avandia, or rosiglitazone maleate, continue to be available with stronger warning.
FDA is not bound to follow the panel recommendations but adopts them frequently.
Journal report
The safety of the GlaxoSmithKline (GSK) drug was called into question in May with the publication of an analytical study in the New England Journal of Medicine, which contended that Avandia increased heart failure risks by 43 per cent.
Dr Abdul Razzak Al Madani, president of Emirates Diabetes Society, told Gulf News physicians should now be careful to explain the risks of the drug, used to treat Type II diabetes.
"There is not enough evidence of the risks compared to other drugs. But we have to explain to the patient and leave the decision to him," he said.
"If it's working fine and there are [no serious side effects], there is no good reason to discontinue it. Unless, of course, the patient requests it," he added.
He stressed that the drug safety scare highlighted the importance of preventing diabetes as "there are no medicines without side effects".
Dr V.J. Sebastian, head of cardiology at Welcare Hospital, told Gulf News he was relieved that the drug remained available although he would be prescribing it less.
"I'm happy because it is a very good drug for patients with insulin resistance," he said. "[But] we will now have to be very careful in selecting patients [to prescribe the drug] and carefully monitor them for heart failure and fluid retention," he added.
He said he used to prescribe Avandia to 40 per cent of his patients. Now, he plans to prescribe to about 30 per cent of patients.
The Health Ministry will not take immediate action on the FDA panel's recommendation of stronger warnings on Avandia.
'No immediate action'
Dr Fatima Ali Abdullah, deputy director of drug control at the ministry, told Gulf News they need time to peruse the recommendation and weigh the risks against the benefits.
In a press release, GSK stated they were happy with the advisory committee's decision.
"We welcome the decision as positive for patients. This was the first opportunity for these scientific experts to review the full data behind Avandia," said Dr Ronald Krall, the company's chief medical officer.
The UAE has the second highest rate of diabetes, according to the International Diabetes Federation.
Latest news
- Dubai Police deny reports of Burj Khalifa fire
- New road eases traffic problems in Dubai
- Abu Dhabi hosts strong man contest
- Farmers to be taught techniques to improve yield
- Keep recycling bins open
- UAE's first home-grown unmanned aerial vehicle
- Telling stories with sand
- President of Wollongong varsity about his plans
- Challenging role in Libya
- Parachuting event promises rich fare
- UAE ministry backs efficacy of Tas'heel system
- UAE students on research trip to Antarctica
- Brothers held in Sharjah for possessing heroin
- Fund drive for displaced Syrians launched
- FNC has kept pace with development — Al Murr
Community Reports
-
Keep recycling bins open
People should be allowed to do their part as the world moves towards a greener future
-
Bridges needed
Al Ittihad Road has no pedestrian facilities as one nears Sharjah
-
Street lights needed
Authorities urged to act with haste before a major accident occurs in Al Nahda, Dubai
-
Motorists ignore stop sign on buses
Overtaking school vehicles can put students' lives at risk
